National Health Commission Key Laboratory of Radiobiology, School of Public Health of Jilin University, Jilin, Changchun 130021, P.R. China.
School of Public Health, Xinxiang Medical University, Xinxiang 453003, P.R. China.
Mol Med Rep. 2023 Mar;27(3). doi: 10.3892/mmr.2023.12953. Epub 2023 Feb 17.
A series of physiological and pathological changes occur after radiotherapy and accidental exposure to ionizing radiation (IR). These changes cause serious damage to human tissues and can lead to death. Radioprotective countermeasures are radioprotective agents that prevent and reduce IR injury or have therapeutic effects. Based on a good understanding of radiobiology, a number of protective agents have achieved positive results in early clinical trials. The present review grouped known radioprotective agents according to biochemical categories and potential clinical use, and reviewed radiation countermeasures, i.e., radioprotectors, radiation mitigators and radiotherapeutic agents, with an emphasis on their current status and research progress. The aim of the present review is to facilitate the selection and application of suitable radioprotectors for clinicians and researchers, to prevent or reduce IR injury.
放疗及意外接触电离辐射(IR)后会发生一系列生理和病理变化。这些变化对人体组织造成严重损害,甚至可能导致死亡。放射防护对策是指预防和减少 IR 损伤或具有治疗作用的放射防护剂。基于对放射生物学的深入了解,许多防护剂在早期临床试验中取得了积极成果。本综述根据生化类别和潜在临床用途对已知的放射防护剂进行了分类,并对放射防护对策,即放射防护剂、放射缓和剂和放射治疗剂进行了综述,重点介绍了它们的现状和研究进展。本综述的目的是为临床医生和研究人员选择和应用合适的放射防护剂提供便利,以预防或减少 IR 损伤。